On July 24, 2025 Kling Bio ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, reported it has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its groundbreaking B cell immortalization and screening platform, Kling-Select (Press release, Kling Biotherapeutics, JUL 24, 2025, View Source [SID1234654511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kling-Select is a proprietary, clinically and commercially validated B cell immortalization platform that has played a pivotal role in the discovery of potent neutralizing antibodies. By leveraging patient-derived B cells, Kling-Select enables rapid identification of novel antibodies and conserved viral epitopes, significantly enhancing vaccine and therapeutic design. Utilizing function-first screening workflow, Kling-Select uncovers rare and highly effective immune targets, accelerating the development of next-generation prophylactics and treatments. The platform’s proven success includes validated antibody candidates against RSV, COVID-19, and influenza, underscoring its broad utility and scientific impact.

The objective of the collaboration is to identify and characterize monoclonal antibodies with potent neutralizing activity against a clinically relevant human viral pathogen. Insights gained from this joint discovery effort may enable the development of next-generaton antiviral therapeutics and inform the design of more efficacious vaccine candidates.

"This collaboration with Sanofi highlights the broad potential of our Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies," commented Michael Koslowski, MD, Chief Executive Officer of Kling Bio. "Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes. We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines."

On July 24, 2025 TriSalus Life Sciences Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, reported the completion of its previously disclosed exchange offer and consent solicitation for its Preferred Stock (Press release, TriSalus Life Sciences, JUL 24, 2025, View Source [SID1234654512]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offer expired one minute after 11:59 p.m. EDT on July 23, 2025. Under the terms of the offer, TriSalus provided holders of its Preferred Stock the option to exchange each preferred share for 3.3 shares of its common stock. As previously disclosed, parties representing approximately 55% of the shares of Preferred Stock have agreed to tender their shares of Preferred Stock in the Offer and to consent to the Preferred Stock Amendment in the Consent Solicitation pursuant to tender and support agreements

The company has been advised that the shares of Preferred Stock tendered represented approximately 98.82% of the outstanding shares of Preferred Stock. All validly tendered shares will be accepted, with settlement expected by August 1, 2025.

Because a sufficient percentage of preferred shareholders agreed to the offer, TriSalus received approval to amend the terms of the Preferred Stock. As a result, the remaining outstanding preferred shares will be automatically converted to common stock at a slightly lower exchange rate (11.3% less than the offered rate).

The SEC declared the company’s Registration Statement on Form S-4 (Registration No. 333-288250), originally filed with the SEC on June 23, 2025, registering the shares issuable in the offer and pursuant to the amendment to Preferred Stock was declared effective by the SEC on July 22, 2025.

TriSalus was assisted in the process by Sodali LLC (Information Agent) and Continental Stock Transfer & Trust Company (Exchange Agent).

On July 24, 2025 Targepeutics, a biotech company dedicated to developing targeted therapies for aggressive pediatric brain cancers, reported a strategic financing round led by the Yuvaan Tiwari Foundation (Press release, Targepeutics, JUL 24, 2025, View Source [SID1234654513]). This investment will directly support the advancement of GB13, Targepeutics’ lead drug candidate, into clinical trials for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) — one of the deadliest pediatric brain tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to welcome the Yuvaan Tiwari Foundation into the Targepeutics community," said Sil Lutkewitte, CEO of Targepeutics. "Their support is more than just financial — it represents a deep, shared commitment to pushing forward the science and bringing hope to families facing DIPG."

GB13 is a first-in-class precision therapy designed to target a key molecular driver of DIPG. Preclinical data have shown promising efficacy, and the new funding will accelerate the operational steps required to initiate a first-in-human trial. The FDA’s Rare Pediatric Disease Designation (RPDD) for GB13 earlier this year underscores its potential impact and makes Targepeutics eligible for a Priority Review Voucher (PRV), which could expedite regulatory review and further support clinical development.

The Yuvaan Tiwari Foundation, created in memory of Yuvaan Tiwari who lost his life to Diffuse Midline Glioma (DMG) at the age of 3, is committed to accelerating breakthrough research and clinical solutions for pediatric brain cancer.

"We lost our son to this disease, and we know what’s at stake. This is more than an investment — it’s a direct action toward changing the outlook for children with DMG," said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. "Our foundation is proud to support Targepeutics’ bold and innovative treatment approach. This investment reflects our focus on advancing therapies with real potential to impact the lives of children facing this devastating disease."

Targepeutics remains focused on pushing the boundaries of what’s possible in pediatric oncology, and this new partnership brings it one step closer to delivering transformative care to the patients who need it most.

On July 24, 2025 Incyte (Nasdaq:INCY) reported that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, to be held October 17-21 in Berlin (Press release, Incyte, JUL 24, 2025, View Source [SID1234654514]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "These data underscore the importance of establishing treatment options for advanced solid tumors and speak to the potential of INCA33890 and INCB161734 as personalized therapies to enhance outcomes for patients with cancer across a range of tumor types."

Details on the abstracts accepted for oral presentation at ESMO (Free ESMO Whitepaper) include:

INCB161734 (KRAS G12D)​

Preliminary Phase 1 Results Of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced Or Metastatic Solid Tumors​
(Session Title: Proffered paper session: Developmental therapeutics. [October 19, 8:45 – 10:15 a.m. ET [2:45 – 4:15 p.m. CEST]. Abstract #916O.)

INCA33890 (PD-1/TGFβR2)​

A Phase 1 Study Of INCA33890, A PD-1/Tgfβr2 Bispecific Antibody, For Advanced Solid Tumours​
(Session Title: Mini oral session: Investigational immunotherapy. [October 17, 8:00 – 9:30 a.m. ET [2:00 – 3:30 p.m. CEST]. Abstract #1522.)

INCAGN2385 (LAG-3)​

Retifanlimab (Anti–PD-1 Mab) Alone Or In Combination With Anti-LAG3 ± Anti-TIM3 Mabs In Previously Untreated, Recurrent And/Or Metastatic (R/M) PD-L1+ HNSCC: A Double-Blind Randomised Controlled Phase 2 Trial
(Session Title: Mini oral session: Head and neck cancer. [October 19, 10:30 a.m. – 12:00 p.m. ET [4:30 – 6:00 p.m. CEST]. Abstract #1325.)

All regular abstracts accepted for presentation at the ESMO (Free ESMO Whitepaper) Congress 2025 will be published online via the ESMO (Free ESMO Whitepaper) website on Monday, October 13 at 6:05 p.m. ET (12:05 a.m. CEST). All accepted abstracts will be published online in the ESMO (Free ESMO Whitepaper) Congress 2025 Abstract Book, a supplement to the official ESMO (Free ESMO Whitepaper) journal, Annals of Oncology.

More information regarding the 2025 ESMO (Free ESMO Whitepaper) Congress can be found at: View Source

On July 24, 2025 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported its financial results for the second quarter of fiscal year 2025 (Press release, Chugai, JUL 24, 2025, View Source [SID1234654499]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chugai reported increased revenue and operating profit year-on-year for the second quarter (Core-basis).

Regarding revenue, domestic sales increased by 2.8%. In the oncology field, sales decreased by 1.9%. While new products Phesgo performed well and Lunsumio steadily penetrated the market, this was offset by the decline in Perjeta and Herceptin along with the market penetration of Phesgo which includes the same active pharmaceutical ingredients. Additionally, products including our mainstay product Avastin were affected by NHI drug price revisions and biosimilars. In the specialty field, sales increased by 8.4%, driven by significant growth of the mainstay product Vabysmo and successful market penetration of the new product PiaSky. Overseas sales increased by 7.3%, driven by a substantial increase in exports of Actemra to Roche. Other revenue decreased by 0.4%, despite the increase in royalty income related to Hemlibra, mainly due to a decrease in one-time income.

Cost to sales ratio increased by 1.3 percentage points year-on-year to 34.3%, mainly due to changes in the product mix. Research and development expenses increased by 2.7% due to investments into drug discovery and early development, and increase associated with the progress of development projects, while selling, general and administrative expenses decreased by 2.6% due to efficient management of various expenses. Other operating income (expense) resulted in income of ¥0.4 billion. As a result, Core operating profit was ¥272.0 billion (+3.5%).

Chugai made good progress in both early and late-stage development activities.

In early-stage development of in-house projects that will drive mid to long-term growth, GYM329 (for obesity) and Hemlibra (for von Willebrand disease) have initiated Phase II and Phase III clinical trials, respectively. Additionally, AUBE00 (for solid tumors), the second clinical-stage project following LUNA18 in our mid-size molecule pipeline, has initiated Phase I clinical trials. In late-stage development, Alecensa has been filed for approval for additional tumor agnostic indication in ALK fusion / rearrangement gene-positive solid tumors, including pediatric patients. In-house projects out-licensed to third parties excluding Roche also progressed steadily, with AVMAPKI, out-licensed to Verastem Oncology, receiving approval from the U.S. Food and Drug Administration (FDA) for use in combination with FAKZYNJA for KRAS-mutated recurrent low-grade serous ovarian cancer, under the accelerated approval pathway* based on overall response rate and duration of response.

Chugai has made the management decision to discontinue our development of five projects from early-stage in-house clinical development pipeline; LUNA18, SAIL66, SOF10, STA551, and AMY109. Since the launch of TOP I 2030 in 2021, we have continuously generated new projects and built technological foundations through enhanced RED functions. The number of early-stage projects has been increasing, with nine in-house projects entering clinical development over the four-year period. For early-stage clinical development pipeline, we have prioritized in-house projects after considering obtained data and the current portfolio situation, resulting in the decision to discontinue these five projects. Through this decision, we aim to maximize the success rate of achieving TOP I 2030 goals through dynamic and strategic allocation of resources to priority projects.

*Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

For products in-licensed from Roche, Elevidys has obtained regulatory approval as a regenerative medicine product for the treatment of Duchenne muscular dystrophy under the conditional and time-limited approval pathway in Japan. Vabysmo has received approval for an additional indication for angioid streaks, and Evrysdi has launched a new formulation in Japan. Lunsumio has been filed for an additional indication in combination with Polivy for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, and Tecentriq has been filed for an additional indication for unresectable thymic cancer. Additionally, Vabysmo (for non-proliferative diabetic retinopathy) and inavolisib (for PIK3CA mutated breast cancer) have initiated new clinical trials.

[2025 second quarter results]

Billion JPY 2025
Jan – Jun 2024
Jan – Jun % change
Core results
Revenue 578.5 552.9 +4.6%
　Sales 511.4 485.5 +5.3%
　Other revenue 67.0 67.3 -0.4%
Operating profit 272.0 262.8 +3.5%
Net income 193.5 189.5 +2.1%
IFRS results
Revenue 578.5 552.9 +4.6%
Operating profit 273.3 258.2 +5.8%
Net income 194.4 186.3 +4.3%
[Sales breakdown]

Billion JPY 2025
Jan – Jun 2024
Jan – Jun % change
Sales 511.4 485.5 +5.3%
Domestic sales 223.3 217.2 +2.8%
　Oncology 116.6 118.8 -1.9%
　Specialty 106.7 98.4 +8.4%
Overseas sales 288.1 268.4 +7.3%
[Oncology field (Domestic) Top5-selling medicines]

Billion JPY 2025
Jan – Jun 2024
Jan – Jun % change
Tecentriq 29.9 31.1 -3.9%
Polivy 17.0 15.7 +8.3%
Alecensa 15.8 14.9 +6.0%
Phesgo 15.4 8.6 +79.1%
Avastin 13.0 17.4 -25.3%
[Specialty field (Domestic) Top5-selling medicines]

Billion JPY 2025
Jan – Jun 2024
Jan – Jun % change
Hemlibra 29.1 27.4 +6.2%
Actemra 23.8 22.4 +6.3%
Enspryng 13.3 11.6 +14.7%
Vabysmo 12.0 9.1 +31.9%
Evrysdi 7.9 7.5 +5.3%
[Progress in R&D activities from Apr 25th, 2025 to Jul 24th, 2025]

2025 Q2 R&D Progress
About Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting Non-Core items to IFRS results. Chugai’s recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and as the basis for payment-by-results such as a return to shareholders.

Trademarks used or mentioned in this release are protected by law.